Chrysin.

Oral chrysin is almost entirely glucuronidated and sulfated in the gut wall before it reaches circulation. Piperine inhibits those UGT and SULT enzymes, which is the standard way formulators raise chrysin exposure.

Standardised piperine slows intestinal glucuronidation, the main reason free chrysin levels stay low after an oral dose. Co-dosing raises the amount that survives first pass.

Chrysin is one of the principal flavones in poplar-type propolis and occurs there alongside galangin, pinocembrin and caffeic acid esters. Propolis delivers chrysin inside its native flavonoid matrix.

Quercetin is a substrate and inhibitor of the same UGT and SULT isoforms that clear chrysin. Co-dosing raises chrysin exposure by competition, and the same is true in the other direction, so total flavonoid load should be counted together.

Apigenin and chrysin differ by a single hydroxyl and share both benzodiazepine-site binding at the GABA-A receptor in receptor work and the same conjugation route. Formulas combine them for an additive flavone effect on normal relaxation signalling.

Luteolin overlaps chrysin in flavone scaffold, aromatase affinity in cell work and phase II clearance. The two are stacked as a flavone group rather than used singly.

Chrysin is one of the flavones isolated from passionflower and binds the benzodiazepine site of the GABA-A receptor. Combining the isolate with the whole extract stacks activity at the same receptor site.

Chrysin acts at aromatase, the step that forms oestrogens, while DIM shifts oestrogen hydroxylation toward the 2-OH route downstream. Formulas pair them to cover formation and clearance rather than one step.

Chrysin has been formulated together with quercetin and rutin in a micellar delivery system that was compared against native flavonoid powder in a randomised crossover pharmacokinetic study. The endpoint there was plasma exposure, a marker of delivery, not a health outcome. The three flavonoids share overlapping phase II conjugation routes, so co-delivery is a formulation decision rather than a demonstrated functional effect.

Chrysin is a lipophilic flavone with low aqueous solubility, which is the first limit on how much ever reaches the gut wall. Phospholipid complexes and lecithin-based micelles are the standard way formulators raise the dissolved fraction of such compounds. The rationale is physicochemical and applies to the delivery step, not to any downstream effect.

Sunflower-derived phosphatidylcholine performs the same emulsifying job as soy lecithin in a flavone dispersion and is chosen when a soy-free label is wanted. It keeps chrysin in a dispersed lipid phase through gastric transit. The pairing is formulation convention and says nothing about activity.

Medium-chain triglycerides dissolve lipophilic plant compounds and are commonly used as the carrier in softgel and liquid presentations. For chrysin the relevant step is keeping the molecule in solution long enough to be taken up. This is a delivery mechanism, not an added effect.

Ascorbate can reduce flavonoid phenoxyl radicals back to the parent phenol in chemical systems, which is why the two are often placed in the same antioxidant blend. Whether that recycling matters at intakes people actually use has not been measured for chrysin specifically. Read it as chemistry rather than a clinical pairing.

N-acetylcysteine supplies cysteine for glutathione synthesis, and the animal work on chrysin reports changes in glutathione and lipid peroxidation markers. Those are markers measured in tissue, not outcomes in people. No combination study in humans exists, so the pairing rests on a shared pathway rather than on data.

Rodent studies of chrysin report glutathione concentration as one of the outcome markers, which places the two in the same redox compartment conceptually. Marker movement in an animal tissue is not an outcome in a person. There is no human combination evidence.

Lipoic acid moves between oxidised and reduced states and participates in the same antioxidant recycling network that flavonoids feed into. Pairing it with chrysin is a formulator's redox-blend choice. No study has measured the two together in humans.

Silymarin flavonolignans and chrysin are both heavy substrates for UDP-glucuronosyltransferases and sulfotransferases in the intestinal wall. Taken together they compete for the same conjugating capacity, which can raise the unconjugated fraction of either one. The direction of that shift has not been quantified for this specific pair.

EGCG and chrysin are both substrates for intestinal sulfotransferases and for BCRP-mediated efflux back into the gut lumen. Co-ingestion sets up competition at those two steps, so systemic exposure to either can shift. The size and direction have not been measured for the pair.

Curcumin is glucuronidated extensively in the enterocyte, the same bottleneck that limits chrysin. Putting both in one capsule loads a single conjugation route. That is a pharmacokinetic interaction to be aware of, not a benefit claim in either direction.

Resveratrol is cleared mainly by sulfation and glucuronidation, the same two routes that dominate chrysin clearance. Co-administration means the two draw on one pool of conjugating capacity. No combination pharmacokinetic study has measured the result.

Alpha-tocopherol works in the membrane lipid phase while flavones act mostly at the aqueous interface, which is the usual argument for combining them. The chrysin animal literature reports lipid peroxidation markers such as malondialdehyde, the same markers tocopherol moves. Marker overlap is not evidence of a combined effect in people.

Chrysin carries the 5-hydroxy-4-keto arrangement that binds ferric iron, the same structural feature behind polyphenol interference with non-heme iron uptake. Taken in the same dose window as an iron supplement it can bind a fraction of that iron in the gut lumen. Separating the two by a couple of hours is the usual formulation answer.

Chrysin and boron appear together in products positioned around normal hormone balance in men. Nothing has been measured for the two together, and the only human work involving chrysin in that space used it inside a multi-ingredient blend. Read it as a formulation convention with no supporting combination data.